10x Genomics (TXG) | Stock Overview & Key Data
10x Genomics Performance Comparison
Stock Range
Today's Range
Low: $13.11
High: $14.30
on August 22, 2025
52 Week Range
Low: $6.78
High: $24.76
on April 7, 2025
on September 3, 2024
All-Time High: $208.99 on June 28, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.7B
EPS
-0.70
P/E Ratio (TTM)
-8.79
Forward P/E
-11.03
P/B Ratio
2.17
PEG Ratio
0.05
Div. Yield
N/A
ROE
-11.30%
Beta
2.028
Debt to Equity
11.22
Financial Highlights
Profitability
Gross Margin
72.34%
Operating Margin
-2.63%
Profit Margin
-13.13%
Returns and Earnings
Return on Assets (TTM)
-9.45%
Return on Equity (TTM)
-11.30%
EBITDA
$-110.9M
Net Income (TTM)
$-84.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$5.27
Quarterly Revenue Growth (YoY)
12.90%
Quarterly Earnings Growth (YoY)
12.93%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| 10x Genomics TXG | 1.68B Small-cap | 7.04% | 10.08% | 67.45% | 26.66% | 0.78% | -39.12% | -59.01% | -87.04% |
| Veeva Systems VEEV | 46.47B Large-cap | 3.68% | 2.02% | 23.53% | 28.68% | 38.17% | 45.98% | 40.86% | 6.13% |
| Ge Healthcare GEHC | 33.40B Large-cap | 2.48% | -1.66% | 8.32% | -16.95% | -4.03% | -11.28% | 32.57% | 32.57% |
| Certara CERT | 1.77B Small-cap | 4.08% | 8.00% | -0.09% | -8.61% | 7.60% | -13.69% | -30.48% | -69.88% |
| GoodRx Holdings GDRX | 1.56B Small-cap | 22.25% | -7.32% | 19.37% | -5.79% | 0.00% | -44.59% | -25.37% | -91.24% |
| Schrodinger SDGR | 1.50B Small-cap | 4.85% | -10.76% | -4.24% | -6.32% | -0.39% | 2.26% | -26.62% | -67.06% |
Ownership & Short Interest
Insider Ownership
1.87%
Institutional Ownership
105.21%
Shares Short
14M
Short Ratio
4.59
Short % of Shares Outstanding
18.64%
Average 10-Day Volume
4M
Average 90-Day Volume
3M
10x Genomics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in 10x Genomics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is TXG's 52-week high and low?
- In the last 52 weeks, 10x Genomics reached a high of $24.76 (on September 3, 2024) and a low of $6.78 (on April 7, 2025).
- What is the market cap and P/E ratio for TXG?
- Curious about 10x Genomics's size and valuation? Its market capitalization stands at 1.68B. When it comes to valuation, the P/E ratio (trailing twelve months) is -8.79, and the forward P/E (looking ahead) is -11.03.
- Does TXG pay dividends? If so, what's the yield?
- As for dividends, 10x Genomics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are 10x Genomics's main competitors or similar companies to consider before investing?
When looking at 10x Genomics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Veeva Systems
VEEV46.47B Healthcare Health Information Services 45.98% 40.86% Ge Healthcare
GEHC33.40B Healthcare Health Information Services -11.28% 32.57% Certara
CERT1.77B Healthcare Health Information Services -13.69% -30.48% GoodRx Holdings
GDRX1.56B Healthcare Health Information Services -44.59% -25.37% Schrodinger
SDGR1.50B Healthcare Health Information Services 2.26% -26.62% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for 10x Genomics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of 10x Genomics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -11.30%, the Debt to Equity ratio from the most recent quarter is 11.22, and its Gross Profit Margin stands at 72.34%.
- What is the recent revenue and earnings growth for TXG?
- Looking at 10x Genomics's growth, its revenue over the trailing twelve months (TTM) was $644M. Compared to the same quarter last year (YoY), quarterly revenue grew by 12.90%, and quarterly earnings saw a YoY growth of 12.93%.
- How much of TXG stock is held by insiders and institutions?
- Wondering who owns 10x Genomics stock? Company insiders (like executives and directors) hold about 1.87% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 105.21%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.